Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Aminopyrimidinone cdc7 kinase inhibitors.

Woods KW, Lai C, Miyashiro JM, Tong Y, Florjancic AS, Han EK, Soni N, Shi Y, Lasko L, Leverson JD, Johnson EF, Shoemaker AR, Penning TD.

Bioorg Med Chem Lett. 2012 Mar 1;22(5):1940-3. doi: 10.1016/j.bmcl.2012.01.041. Epub 2012 Jan 25.

PMID:
22326396
2.

Synthesis and SAR of novel tricyclic quinoxalinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1).

Miyashiro J, Woods KW, Park CH, Liu X, Shi Y, Johnson EF, Bouska JJ, Olson AM, Luo Y, Fry EH, Giranda VL, Penning TD.

Bioorg Med Chem Lett. 2009 Aug 1;19(15):4050-4. doi: 10.1016/j.bmcl.2009.06.016. Epub 2009 Jun 13.

PMID:
19553114
3.

Akt inhibitor a-443654 interferes with mitotic progression by regulating aurora a kinase expression.

Liu X, Shi Y, Woods KW, Hessler P, Kroeger P, Wilsbacher J, Wang J, Wang JY, Li C, Li Q, Rosenberg SH, Giranda VL, Luo Y.

Neoplasia. 2008 Aug;10(8):828-37.

4.

Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity.

Johnson EF, Stewart KD, Woods KW, Giranda VL, Luo Y.

Biochemistry. 2007 Aug 21;46(33):9551-63. Epub 2007 Jul 27.

PMID:
17655330
5.

Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.

Zhu GD, Gandhi VB, Gong J, Thomas S, Woods KW, Song X, Li T, Diebold RB, Luo Y, Liu X, Guan R, Klinghofer V, Johnson EF, Bouska J, Olson A, Marsh KC, Stoll VS, Mamo M, Polakowski J, Campbell TJ, Martin RL, Gintant GA, Penning TD, Li Q, Rosenberg SH, Giranda VL.

J Med Chem. 2007 Jun 28;50(13):2990-3003. Epub 2007 May 25.

PMID:
17523610
6.

Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition.

Han EK, Leverson JD, McGonigal T, Shah OJ, Woods KW, Hunter T, Giranda VL, Luo Y.

Oncogene. 2007 Aug 16;26(38):5655-61. Epub 2007 Mar 5.

PMID:
17334390
7.

Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors.

Woods KW, Fischer JP, Claiborne A, Li T, Thomas SA, Zhu GD, Diebold RB, Liu X, Shi Y, Klinghofer V, Han EK, Guan R, Magnone SR, Johnson EF, Bouska JJ, Olson AM, de Jong R, Oltersdorf T, Luo Y, Rosenberg SH, Giranda VL, Li Q.

Bioorg Med Chem. 2006 Oct 15;14(20):6832-46. Epub 2006 Jul 14.

PMID:
16843670
8.

Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase.

Thomas SA, Li T, Woods KW, Song X, Packard G, Fischer JP, Diebold RB, Liu X, Shi Y, Klinghofer V, Johnson EF, Bouska JJ, Olson A, Guan R, Magnone SR, Marsh K, Luo Y, Rosenberg SH, Giranda VL, Li Q.

Bioorg Med Chem Lett. 2006 Jul 15;16(14):3740-4. Epub 2006 May 5.

PMID:
16678413
9.

Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity.

Zhu GD, Gong J, Claiborne A, Woods KW, Gandhi VB, Thomas S, Luo Y, Liu X, Shi Y, Guan R, Magnone SR, Klinghofer V, Johnson EF, Bouska J, Shoemaker A, Oleksijew A, Stoll VS, De Jong R, Oltersdorf T, Li Q, Rosenberg SH, Giranda VL.

Bioorg Med Chem Lett. 2006 Jun 15;16(12):3150-5. Epub 2006 Apr 5.

PMID:
16603355
10.

Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.

Li Q, Woods KW, Thomas S, Zhu GD, Packard G, Fisher J, Li T, Gong J, Dinges J, Song X, Abrams J, Luo Y, Johnson EF, Shi Y, Liu X, Klinghofer V, Des Jong R, Oltersdorf T, Stoll VS, Jakob CG, Rosenberg SH, Giranda VL.

Bioorg Med Chem Lett. 2006 Apr 1;16(7):2000-7. Epub 2006 Jan 18.

PMID:
16413780
11.

Optimal classes of chemotherapeutic agents sensitized by specific small-molecule inhibitors of akt in vitro and in vivo.

Shi Y, Liu X, Han EK, Guan R, Shoemaker AR, Oleksijew A, Woods KW, Fisher JP, Klinghofer V, Lasko L, McGonigal T, Li Q, Rosenberg SH, Giranda VL, Luo Y.

Neoplasia. 2005 Nov;7(11):992-1000.

12.

RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors.

Morgan-Lappe S, Woods KW, Li Q, Anderson MG, Schurdak ME, Luo Y, Giranda VL, Fesik SW, Leverson JD.

Oncogene. 2006 Mar 2;25(9):1340-8.

PMID:
16247451
13.

Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo.

Luo Y, Shoemaker AR, Liu X, Woods KW, Thomas SA, de Jong R, Han EK, Li T, Stoll VS, Powlas JA, Oleksijew A, Mitten MJ, Shi Y, Guan R, McGonigal TP, Klinghofer V, Johnson EF, Leverson JD, Bouska JJ, Mamo M, Smith RA, Gramling-Evans EE, Zinker BA, Mika AK, Nguyen PT, Oltersdorf T, Rosenberg SH, Li Q, Giranda VL.

Mol Cancer Ther. 2005 Jun;4(6):977-86.

14.

Benzimidazolones and indoles as non-thiol farnesyltransferase inhibitors based on tipifarnib scaffold: synthesis and activity.

Li Q, Li T, Woods KW, Gu WZ, Cohen J, Stoll VS, Galicia T, Hutchins C, Frost D, Rosenberg SH, Sham HL.

Bioorg Med Chem Lett. 2005 Jun 2;15(11):2918-22. Epub 2005 Apr 21.

PMID:
15911281
15.

Design, synthesis, and activity of achiral analogs of 2-quinolones and indoles as non-thiol farnesyltransferase inhibitors.

Li Q, Woods KW, Wang W, Lin NH, Claiborne A, Gu WZ, Cohen J, Stoll VS, Hutchins C, Frost D, Rosenberg SH, Sham HL.

Bioorg Med Chem Lett. 2005 Apr 15;15(8):2033-9.

PMID:
15808463
16.

Synthesis and activity of 1-aryl-1'-imidazolyl methyl ethers as non-thiol farnesyltransferase inhibitors.

Li Q, Wang GT, Li T, Gwaltney SL 2nd, Woods KW, Claiborne A, Wang X, Gu W, Cohen J, Stoll VS, Hutchins C, Frost D, Rosenberg SH, Sham HL.

Bioorg Med Chem Lett. 2004 Nov 1;14(21):5371-6.

PMID:
15454229
17.

For love of the profession. Award winners take leadership to new heights.

Royer TC, Woods KW, Woods GW, Miller SR.

MGMA Connex. 2003 Oct;3(9):44-55. No abstract available.

PMID:
14571592
18.

Biological activity of A-289099: an orally active tubulin-binding indolyloxazoline derivative.

Tahir SK, Nukkala MA, Zielinski Mozny NA, Credo RB, Warner RB, Li Q, Woods KW, Claiborne A, Gwaltney SL 2nd, Frost DJ, Sham HL, Rosenberg SH, Ng SC.

Mol Cancer Ther. 2003 Mar;2(3):227-33.

19.

Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation.

Wang L, Woods KW, Li Q, Barr KJ, McCroskey RW, Hannick SM, Gherke L, Credo RB, Hui YH, Marsh K, Warner R, Lee JY, Zielinski-Mozng N, Frost D, Rosenberg SH, Sham HL.

J Med Chem. 2002 Apr 11;45(8):1697-711. Erratum in: J Med Chem 2002 Oct 24;45(22):4946.

PMID:
11931625
20.

Synthesis and biological evaluation of 2-indolyloxazolines as a new class of tubulin polymerization inhibitors. Discovery of A-289099 as an orally active antitumor agent.

Li Q, Woods KW, Claiborne A, Gwaltney SL 2nd, Barr KJ, Liu G, Gehrke L, Credo RB, Hui YH, Lee J, Warner RB, Kovar P, Nukkala MA, Zielinski NA, Tahir SK, Fitzgerald M, Kim KH, Marsh K, Frost D, Ng SC, Rosenberg S, Sham HL.

Bioorg Med Chem Lett. 2002 Feb 11;12(3):465-9.

PMID:
11814821
21.

Thiazole analogues of the NSAID indomethacin as selective COX-2 inhibitors.

Woods KW, McCroskey RW, Michaelides MR, Wada CK, Hulkower KI, Bell RL.

Bioorg Med Chem Lett. 2001 May 21;11(10):1325-8.

PMID:
11392547
22.

Heteroarylmethoxyphenylalkoxyiminoalkylcarboxylic acids as leukotriene biosynthesis inhibitors.

Kolasa T, Gunn DE, Bhatia P, Woods KW, Gane T, Stewart AO, Bouska JB, Harris RR, Hulkower KI, Malo PE, Bell RL, Carter GW, Brooks CD.

J Med Chem. 2000 Feb 24;43(4):690-705.

PMID:
10691695
23.

Studies directed toward the design of orally active renin inhibitors. 1. Some factors influencing the absorption of small peptides.

Rosenberg SH, Spina KP, Woods KW, Polakowski J, Martin DL, Yao Z, Stein HH, Cohen J, Barlow JL, Egan DA, et al.

J Med Chem. 1993 Feb 19;36(4):449-59.

PMID:
8474101
24.

Water-soluble renin inhibitors: design of a subnanomolar inhibitor with a prolonged duration of action.

Rosenberg SH, Woods KW, Sham HL, Kleinert HD, Martin DL, Stein H, Cohen J, Egan DA, Bopp B, Merits I, et al.

J Med Chem. 1990 Jul;33(7):1962-9.

PMID:
2194033
25.

Potent, low molecular weight renin inhibitors containing a C-terminal heterocycle: hydrogen bonding at the active site.

Rosenberg SH, Dellaria JF, Kempf DJ, Hutchins CW, Woods KW, Maki RG, de Lara E, Spina KP, Stein HH, Cohen J, et al.

J Med Chem. 1990 Jun;33(6):1582-90.

PMID:
2187994
26.

Azido glycols: potent, low molecular weight renin inhibitors containing an unusual post scissile site residue.

Rosenberg SH, Woods KW, Kleinert HD, Stein H, Nellans HN, Hoffman DJ, Spanton SG, Pyter RA, Cohen J, Egan DA, et al.

J Med Chem. 1989 Jun;32(6):1371-8.

PMID:
2657067
27.

Novel renin inhibitors containing analogues of statine retro-inverted at the C-termini: specificity at the P2 histidine site.

Rosenberg SH, Plattner JJ, Woods KW, Stein HH, Marcotte PA, Cohen J, Perun TJ.

J Med Chem. 1987 Jul;30(7):1224-8.

PMID:
3298652

Supplemental Content

Loading ...
Support Center